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Abstract
Background: Elderly patients are particularly vulnerable to adverse drug reactions, especially if they are affected by
additional risk factors such as multimorbidity, polypharmacy, impaired renal function and intake of drugs with high
risk potential. Apart from these clinical parameters, drug safety and efficacy can be influenced by pharmacogenetic
factors. Evidence-based recommendations concerning drug-gene-combinations have been issued by international
consortia and in drug labels. However, clinical benefit of providing information on individual patient factors in a
comprehensive risk assessment aiming to reduce the occurrence and severity of adverse drug reactions is not
evident. Purpose of this randomized controlled trial is to compare the effect of a concise individual risk information
leaflet with standard information on risk factors for side effects.
Methods/Design: The trial was designed as a prospective, two-arm, randomized, controlled, multicenter, pragmatic
study. 960 elderly, multimorbid outpatients in general medicine are included if they take at least one high risk and
one other long-term drug (polymedication). As high risk “index drugs” oral anticoagulants and antiplatelets were
chosen because of their specific, objectively assessable side effects. Following randomization, test group patients
receive an individualized risk assessment leaflet evaluating their personal data concerning bleeding- and
thromboembolic-risk-scores, potential drug-drug-interactions, age, renal function and pharmacogenetic factors.
Control group patients obtain a standardized leaflet only containing general information on these criteria.
Follow-up period is 9 months for each patient. Primary endpoint is the occurrence of a thromboembolic/bleeding
event or death. Secondary endpoints are other adverse drug reactions, hospital admissions, specialist referrals and
medication changes due to adverse drug reactions, the patients’ adherence to medication regimen as well as
health related quality of life, mortality and resulting costs.
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Discussion: Despite extensive evidence of risk factors for adverse drug reactions, there are few prospective trial
data about an individualized risk assessment including pharmacogenetic information to increase patient safety. By
conducting a health economic analysis, we will evaluate if the application of an individualized drug therapy in daily
routine is cost-effective.
Trial registration: German Clinical Trials Register: DRKS00006256, date of registration 09/01/15.
Keywords: Individualized medicine, Adverse drug reaction, Elderly, Pharmacogenetics, Polymedication, Drug
interaction, ADR risk assessment, Clinical decision support system
Background
Adverse drug reactions (ADR) represent a major public
health issue not only due to the morbidity and mortality
but also due to the extra costs they cause. About 5–10 %
of all hospital admissions are estimated to be ADR-
associated, 2–6 % of them are fatal [1–5]. According to
analyses of ADR case reports, approximately 40–60 % of
all ADR are considered to be preventable [2, 3, 5, 6]. It has
been reported that the incidence of ADR increases with
age [1, 4–6]. This may be explained by age-related changes
in pharmacokinetics, such as increased drug concentra-
tions due to decreased total body water and impaired
renal function [7, 8]. Additionally, the prevalence of multi-
morbidity and polypharmacy is very high in the elderly [9,
10]. In a recent systematic review on ADR in the elderly,
these two parameters have been mentioned as significant
risk factors for ADR, alongside female sex, impaired renal
function, drug-drug-interactions and drugs with narrow
therapeutic index, e. g. anticoagulants [11].
Pharmacogenetic factors are known to influence dosing
and drug efficacy in patients [12]. For example, clopido-
grel effectiveness depends on its transformation into an
active metabolite by the genetically variable enzyme cyto-
chrome P 450 2C19 (CYP2C19). Reduced enzyme func-
tion has been shown to be significantly associated with
decreased platelet inhibition [13–15]. For vitamin K an-
tagonists, cytochrome P 450 2C9 (CYP2C9) is the main
drug metabolizing enzyme, and vitamin K epoxide reduc-
tase (VKORC1) represents the drugs’ target. They have
been shown to significantly influence dosing requirements
and anticoagulation stability [16–18]. Evidence-based rec-
ommendations for these drugs according to the respective
genotypes have been published by the Royal Dutch Phar-
macists Association - Pharmacogenetics Working Group
[19] and the Clinical Pharmacogenetics Implementation
Consortium (CPIC) [20]. The European Medicines
Agency (EMA) and the U.S. Food and Drug Administra-
tion (FDA) have included pharmacogenetic information
for clopidogrel in the drug labels, the FDA also for the
vitamin k antagonist warfarin [21, 22].
Another measure to increase patient safety is the use
of computerized clinical decision support systems. They
have been shown to be a cost-effective possibility to
reduce preventable ADR and medication errors in in-
patient and ambulatory care [23–26]. Furthermore, some
randomized controlled trials investigating the effect of a
comprehensive medication review in elderly populations
have suggested a reduction of medication-related hos-
pital admissions, but the studies were underpowered and
the results were not statistically significant [27, 28].
Therefore, a randomized controlled trial with a large co-
hort of patients at particularly high risk for ADR is
needed for further investigation.
The aim of this study is to test if individualization of
drug therapy based on the most important categories of
relevant known ADR risk factors may improve safety
and individual efficacy of drug therapy if the doctor and
the patient are getting this information in a timely and
easy-to-understand format. We focus our study on a col-
lective of elderly, multimorbid, polymedicated ADR-high
risk patients. As antithrombotics range among the most
frequently ADR-associated drugs leading to hospitaliza-
tions in the elderly [29, 30] and have high potential for
particularly severe ADR [31, 32], these drugs were deter-
mined as index medication for the study.
Methods/Design
Study aim
The aim of the study is to evaluate the effect of an indi-
vidualized comprehensive risk assessment and informa-
tion leaflet regarding medication compared to a
standardized one on adverse drug reactions in an elderly
high risk population.
Design
The IDrug-study is a prospective, multicenter, two-arm,
randomized, controlled, pragmatic trial. Eligible patients
are randomized to either test or control group. Control
group patients receive a standardized information leaflet
about risk factors for ADR. An individualized leaflet
containing the same general information plus an add-
itional individualized risk assessment is handed out to
test group patients. In the following passages, the study
design will be described in detail.
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Study endpoints
Primary endpoint is the occurrence of a thromboembolic
or bleeding event or death within a 9 months study
period. Secondary endpoints are the occurrence of other
ADR, the number of hospital admissions due to ADR,
the number of specialist referrals due to ADR, the num-
ber of medication changes, the patients’ adherence to
the medication regimen, time to death, health-related
quality of life, costs of medication and of additional gen-
eral practitioner (GP) consultations and hospital treat-
ments as well as a cost-benefit analysis.
Inclusion and exclusion criteria
Patients are eligible if they are at least 60 years old, have
more than one chronic disease and take two or more
prescription drugs. They have to be on long-term treat-
ment with oral anticoagulants (phenprocoumon, war-
farin, dabigatran, apixaban, rivaroxaban) or antiplatelets
(clopidogrel, prasugrel, ticagrelor, ticlopidin) as high risk
index medication. Furthermore, they must be physically
and mentally able to give written consent to participate
in the study. Patients will be excluded if they are unable
to give consent or unable to fill in the required question-
naires (SF-36 for health-related quality of life [33], Mor-
isky score for adherence to medication regimen [34] and
social state).
Sample size
Sample size calculation was based on the primary end-
point and its primary analysis. Preceding studies re-
ported incidence rates ranging from 8 to 10.6 % for
thromboembolic and bleeding events in a population of
elderly polymedicated patients on oral anticoagulants
[32, 35]. Thus, for sample size calculation, we assumed
an incidence rate of 10 % in the control group, which we
assumed to be reduced by half as a result of the individ-
ualized risk assessment (i.e. to 5 %). To detect this antic-
ipated difference with a power of 80 % using the
Cochran-Mantel-Haenszel test (assuming equal effects
in all strata), a sample size of 435 patients per arm is re-
quired. Assuming a dropout rate of 10 % about 960 pa-
tients need to be included in the study.
Recruitment
The study is conducted in the area of Bonn, Cologne
and the Rhine-Sieg-district, Germany. 40–80 GP-
practices situated in this area participate in the study.
After being instructed by the Institute of General Prac-
tice and Family Medicine Bonn, the general practitioners
create a list of eligible patients. They name the number
of patients to the institute and in return obtain in a first
step a random selection of 10 patients to be asked by
the GP to participate in the study. This random selection
is performed using prefabricated lists provided by the
Department of Biostatistics of the Federal Institute for
Drugs and Medical Devices Bonn to avoid selection bias.
Overall each GP-practice is planned to enroll 12–24 pa-
tients. The workflow of the IDrug study is illustrated in
Fig. 1.
Patient information and inclusion
Written informed consent is obtained by the general
practitioner. After enrollment, a blood sample is taken
and sent to the accredited Institute of Clinical Chemistry
and Clinical Pharmacology of the University of Bonn for
genotyping (CYP2C9, CYP2C19 and VKORC1). The pa-
tient’s medical history is documented on paper-based
Case Report Forms (CRF). The collected data include
the patient’s demographic data, such as age, gender,
weight, height, blood test results (creatinine, thrombo-
cytes, hemoglobin and liver enzymes), alcohol consump-
tion, smoking state, anticoagulation/antiplatelet therapy
regimen, medication and diagnoses. Additionally, the
HAS-BLED-Score [36] for bleeding risk (hypertension,
abnormal renal/liver function, stroke, bleeding history or
predisposition, labile internationalized normalized ratio,
elderly (>65 years), drugs/alcohol concomitantly) and
the CHA2DS2-VASc-Score [37] for thromboembolic risk
(congestive heart failure, hypertension, age, diabetes,
stroke, vascular disease, age, sex category) are recorded.
Once completely filled in, the CRF is faxed to the Fed-
eral Institute for Drugs and Medical Devices Bonn for
randomization and risk assessment.
Randomization
Randomization is performed upon receipt of the CRF
and is stratified by GP-practice and gender to account
for potential influence of GP and gender and to ensure
balanced groups within each stratum. Randomization
lists are provided by the Biostatistics Unit of the Federal
Institute for Drugs and Medical Devices Bonn. Accord-
ing to the allocated study-arm, either a standardized or
an individualized risk assessment leaflet is written and
sent out to the GP in duplicate, as one copy will be
handed out to the patient.
Risk assessment
Both risk assessment leaflets contain general information
on risk factors for adverse drug reactions. However, the
individualized leaflet also includes an additional person-
alized risk evaluation which takes the patients clinical
data into account. For test group patients, their individ-
ual HAS-BLED- and CHA2DS2-VASc-Scores are calcu-
lated. The current medication is checked for potential
drug-drug-interactions and it is checked whether dose
adjustments related to the patients’ kidney function
would apply, using two independent validated evidence-
based clinical decision support systems, AiDKlinik® [38]
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and the ABDA database [39]. Furthermore, the patients’
genetic profiles for CYP2C9, CYP2C19 and VKORC1 are
matched with their medication to check for potential
drug-gene-interactions according to their genotypes.
References are the guidelines published by the Royal
Dutch Pharmacists Association - Pharmacogenetics
Working Group [19] and the Clinical Pharmacogenetics
Implementation Consortium (CPIC) [20]. The standard-
ized leaflet, however, only contains general information
about these risk factors for adverse drug reactions.
The leaflets have a short and clearly arranged design
in order to be implementable in everyday practice. They
only contain clinically relevant information. Additionally,
they are written in a generally understandable manner,
Elderly high risk patients 
• Age 60
• Long-term treatment with oral anticoagulant or antiplatelet 
• At least one additional long term medication
• Multimorbidity
• Written consent







-Genotyping for CYP2C9, CYP2C19 and 
VKORC1
Standardized risk assessment






Primary end point: occurence of thromboembolic / bleeding event or death 
Secondary end points:
Morbidity:
• Other adverse drug reactions 
• Number of hospital admissions due to ADR 
• Number of specialist referrals due to ADR 
• Number of medication changes
• Adherence to medication regimen
Mortality
• Time to death 
Efficiency
• Health related quality of life (SF-36) after 3, 6 and 9 months
• Costs of medication, additional GP-consultations and hospitalizations
• Cost-effectiveness regarding morbidity and mortality
List of eligible patients
Random patient selection
n=12-24 patients per GP are included after written informed consent
n=480 n=480
n=9609 months follow-up
Fig. 1 Workflow IDrug study. Each GP provides a list of all patients meeting the inclusion criteria. The order of patient enrollment is random.
Following randomization to a study arm, the patients receive either a standardized or an individualized risk assessment leaflet and are followed
up for 9 months. 870 patients will be required, and considering an estimated dropout rate of 10 % 960 patients need to be included. At the end
of the study, both groups will be compared regarding primary and secondary endpoints
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so that they can be read easily by doctors as well as pa-
tients. A scheme of the risk assessment leaflets is dis-
played in Fig. 2.
Follow-up and blinding
Follow-up time is 9 months for each patient. Overall, 4
visits are scheduled at intervals of 3 months. The study
starts at visit 1 when the patient receives the risk assess-
ment leaflet. During this visit, the general practitioner
hands out the leaflet and explains its contents to the pa-
tient. It is at the discretion of the GP in which way and to
what extent he uses the provided information for further
treatment, no specifications are made. Patients are consid-
ered to be blinded to group assignment, since group as-
signment is not actively communicated at any time and
both risk assessment leaflets have a very similar layout.
During each visit, the following information is docu-
mented in the CRF: reason for GP-consultation, vital
signs, ECOG score for the patient’s physical condition
[40], adverse events (bleeding events, thromboembolic
events and others), number of GP-consultations in the
meantime, specialist referrals, hospital admissions, sick
leaves, remedies and aids and other procedures (e. g.
emergency department visits, rehabilitation etc.). Data
about anticoagulation/antiplatelet therapy regimen,
medication and diagnoses are updated during each visit.
Additionally, patients are asked to fill in questionnaires
about their health related quality of life (SF-36 [33],
filled in at each visit), their adherence to the medication
regimen [34] (filled in at the beginning and end of the
study) and their social state (filled in once at the begin-
ning of the study).
Data management and monitoring
The patients’ data is documented on paper-based Case
Report Forms by the general practitioners, the practice
General information on the HAS-BLED- and CHA2DS2-VASc-Score Both versions
HAS-BLED-and CHA2DS2-VASc-Score calculation
Information on the individual bleeding risk and risk-benefit-ratio 
of an anticoagulation therapy
Only test 
group
General information on drug-drug interactions Both versions




General information on age-related medication problems Both versions




General information on age-related changes in renal function Both versions
GFR calculation and evaluation of chronic kidney disease stage
Medication review and information on potential dose  
adjustments based on individual renal function
Only test 
group
General information on pharmacogenetic factors Both versions
Individual CYP2C9, CYP2C19 and VKORC1 genotype




Fig. 2 Scheme of the risk assessments. Both versions of risk assessment leaflets contain general information on the following risk factors for ADR:
HAS-BLED- and CHA2DS2-VASc-Score, drug-drug-interactions, age, renal function and pharmacogenetic factors. The individualized risk assessments
additionally include a personalized evaluation of the patient’s personal data
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staff and staff of the Institute of General Practice and
Family Medicine Bonn. It is transferred to a GCP con-
form electronic database by the data management of the
Federal Institute for Drugs and Medical Devices Bonn.
To guarantee data quality, double data entry is per-
formed. Queries are documented in an electronic data-
base and processed during monitoring visits. For each
practice, three of these visits are scheduled. The first one
takes place after inclusion of 1 to 3 patients, the second
one after inclusion of 10 to 15 patients and the third one
when the practice finishes the study. Furthermore, prac-
tices are monitored via telephone and additional interim
visits regularly. Monitoring is performed by the Study
Center of the Institute of Clinical Chemistry and Clinical
Pharmacology, University of Bonn.
Dropout criteria
Study participation is terminated if the patient with-
draws consent or if continuous data collection cannot be
guaranteed (e. g. if the patient changes the GP or is ab-
sent for a long time). Discontinuation of anticoagulant/
antiplatelet therapy after start of the study and receipt of
the risk assessment leaflet (visit 1) does not lead to
exclusion.
Ethic approval, data protection and funding
The IDrug study has been approved by the Ethics
Comittees of the University of Bonn, of the Medical As-
sociation of North Rhine and of the Medical Association
of Rhineland-Palatinate. It is performed according to the
study protocol, ICH-GCP criteria, EU directives and ap-
plicable legal requirements. According to the Declar-
ation of Helsinki, written consent is obtained after oral
and written information. Person-identifying data, such
as names and birthdays, remain at the GP-practices at
all times. All data will be stored for 10 years. Patient in-
formation is pseudonymized before transfer to the Fed-
eral Institute for Drugs and Medical Devices or the
Institute of Clinical Chemistry and Clinical Pharmacol-
ogy. The IDrug study is financially supported by the Fed-
eral Ministry of Education and Research (BMBF). The
protocol has been peer-reviewed in a strictly competitive
process with several external reviewers from non-
German countries evaluating the grant applications.
Statistical analysis
Primary endpoint
The proportion of patients with an event (i. e. thrombo-
embolic or bleeding event or death) will be compared
between the two study arms using the Cochran-Mantel-
Haenszel-Test stratified by gender and medical practice.
Following the intention-to-treat principle, all random-
ized patients will be analyzed according to their random-
ized allocation. Dropouts will be counted as treatment
failure in primary analysis. Risk reduction is estimated
by the Mantel-Haenszel estimator of the common rela-
tive risk with the corresponding 95 % confidence inter-
val. Additional sensitivity analyses will be performed,
which include evaluation of different covariate
structures.
Secondary endpoints
The SF-36-questionnaire for health related quality of life
will be analyzed with a mixed model for repeated mea-
surements using an unstructured covariance matrix .
The mixed model contains the categorical covariates
treatment, visit, gender and medical practice, a continu-
ous covariate for the baseline SF-36-score and a treat-
ment by visit interaction. Evaluation of drug-associated
morbidity involves descriptive analysis of the number of
patients with severe adverse drug reactions, the number
of hospital admissions and specialist referrals due to
ADR and the number of medication changes during the
study period. The adherence scale will be evaluated
using the non-parametric Wilcoxon-test. Survival time
will be analyzed using a log-rank-test stratified by gender
and medical practice. Additionally, a Cox-regression,
which includes covariates treatment, gender, medical
practice, age group and anticoagulant as well as a treat-
ment by gender interaction, will be performed as a sensi-
tivity analysis. The direct costs of the prescribed
medication, unexpected GP-visits and hospitalizations
will be collected and used for a cost-effectiveness ana-
lysis to compare the two study groups. In this context,
two types of health outcomes will be examined. Firstly,
the incidence of adverse events and secondly, the
quality-adjusted-life-years (QALY) measures using the
SF-36-questionnaire.
Discussion
Objective of the IDrug study is to further investigate in-
dividual patient ADR risk factors in a randomized con-
trolled fashion in a real-world clinical setting with
elderly patients at high risk for ADR. In contrast to pre-
ceding clinical studies, clinical and pharmacogenetic risk
factors are not considered in isolation, but together
resulting in a comprehensive medication review in form
of a risk assessment leaflet. The pragmatic study design
does not only allow to obtain valuable data with high
external validity, but also paves the way for clinical
applicability. For the purpose of realistic conditions, GP-
practices were chosen as study sites. Due to the inclu-
sion criteria a broad representative patient population
can be acquired. The high risk characteristic of the study
cohort might enhance detection rates of adverse drug
reactions.
One limitation of the study is that the degree of accur-
acy of blinding might decrease over the study period, as
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each GP will receive both versions of risk assessment
leaflets and, therefore, might be able to identify study
groups during the course of the trial. In contrast, pa-
tients only get to see their own risk assessment leaflets.
Therefore, it is less likely that blinding is broken for pa-
tients. Furthermore, although the provided risk assess-
ment covers the most important risk factors for ADR,
some parameters are not included, e. g. drug-disease in-
teractions and missing drug indications. The reason is to
keep the leaflets as short as possible to ensure the GP’s
and patient’s motivation to read it.
To our knowledge, IDrug is the first randomized con-
trolled trial evaluating the impact of a comprehensive in-
dividualized risk assessment including genotyping on
adverse drug reactions in a large elderly high risk popu-
lation. Based on the study results, we will evaluate
whether this individualized approach has the potential to
increase patient safety in daily routine by reducing ADR
in a cost-effective way. This may advance development
of rational, evidence-based policies for the application of
pharmacogenetic testing in individualized drug therapy
in clinical practice.
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